The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 31, 2017
Filed:
Apr. 20, 2017
Applicant:
Alexion Pharmaceuticals, Inc., New Haven, CT (US);
Inventors:
Bruce A. Andrien, Jr., Guilford, CT (US);
Douglas L. Sheridan, Branford, CT (US);
Paul P. Tamburini, Kensington, CT (US);
Yi Wang, Woodbridge, CT (US);
Assignee:
Alexion Pharmaceuticals, Inc., New Haven, CT (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/36 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/526 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.